|
PET for aggressive T-cell lymphoma?
Clinical Use of PET-based imaging in lymphoma -
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PET imaging based on Lymphoma Type and Clinical Setting | |||||
|
PET-based |
Aggressive lymphoma |
Indolent |
< Indolent > |
indolent |
Hodgkin Lymphoma |
| Initial Staging | Most do |
Most do |
Most do |
Most do |
Most do |
| Interim treatment response |
Investigational | Investigational | Investigational | Investigational | Predictive, but investigational |
| Post treatment response |
YES | Most do | Most do | Most do | YES |
| Surveillance* | not recommended |
not recommended |
not recommended |
not recommended |
not recommended |
* Surveillance scans are used to monitor the disease status or to test for recurrence on a regular schedule
... before (for indolent lymphoma) or
... after completion of a primary therapy for indolent or aggressive lymphoma.2010 - Dr. Rebecca Elstrom shared her perspective
on the clinical use of PET-based imaging in lymphoma"I suspect you will get different answers to these issues, which suggests that very little is actually certain and agreed upon.
I would venture that the only thing just about everyone agrees on is PET for post-treatment response assessment in Aggressive and Hodgkin lymphomas (not indolent--this is still controversial and many still argue that CT is just as good for standard care, though many patients get it anyway).
For initial staging, most do PET for aggressive and Hodgkin, though it rarely changes management and some experts argue that it is unnecessary.
PET in indolent lymphoma would be considered appropriate pre-treatment mostly in 2 settings: if thought to be localized with potential for cure with radiation, or if there is concern for transformation. Although in practice many patients get them anyway, most patients with known advanced stage, "normal" presentation indolent lymphomas do not necessarily need a PET.
Interim therapy PET is investigational in all settings. Although proven to be predictive in Hodgkin, we don't yet know what to do with the information (studies are ongoing and we should have answers soon). For DLBCL, positive vs. negative PET is not predictive, but studies are evaluating the potential utility of quantitative assessment (i.e. whether a percentage decrease in SUV, or intensity of uptake of the tracer, is predictive). For indolent lymphoma, there is minimal information.
Most would agree that PET should not be used for surveillance* due to high incidence of false positives, though a small minority of investigators would disagree."
PET protocols are not yet standardized in regular practice -- that is, it can be done differently at various centers, which can affect the SUV readings:
(1) the dose of the tracer,
(2) the length of the scan,
(3) your blood sugar levels,
(4) how long after therapy,
(5) the type of therapy (chemo / Rituxan / RIT) ...
all can influence the readings. So it's not yet an exact science.Generally, concern increases if the SUV in one tumor region is many times greater than in another tumor area ... but your doctor will know about this and discuss this if it is.
Inflammation can also cause higher SUV readings. So PET is not used to diagnose a lymphoma, but it can help guide where to biopsy. For example, the surgeon will remove (if feasible / safe) the node with the highest SUV to increase the chance of getting a reliable diagnosis.The use of PET to judge if a treatment is effective early (after one or two rounds of therapy) will require standardized methods of using PET -- and clinical research to confirm that the test can be used reliably for this purpose for the different subtypes of lymphoma.
Advocacy note: patients might be provided with a procedure checklist as a quality control -- to help improve compliance with standards for administering a PET in general practice, should this use of PET be confirmed as clinically useful by well-designed clinical trials.
Following completion of treatment the use of PET to determine if residual masses visible by CT imaging is viable (still lymphoma) or is scar tissue is widely considered conclusive for that region.
FDG (2-Fluoro-2-Deoxy-D-Glucose) is a positron emitting radio-pharmaceutical. FDG emits positrons that make gamma rays which the PET scanner detects. It's half life is about 110 minutes. So you will pose no risk to others shortly after the test is done - about 1.2 hours.
(Corrected definition submitted kindly by Dr. Williams)
Search for ACR accredited Diagnostic Imaging Centers
ACR accreditation means:
"Your hospital, clinic or health center has voluntarily gone through a rigorous review process to be sure it meets nationally accepted standards. The personnel are well qualified, through education and certification, to perform and interpret your medical images and administer your radiation therapy treatments. The equipment is appropriate for the test or treatment you will receive, and the facility meets or exceeds quality assurance and safety guidelines."
|
You will be asked to fast before the PET scan. |
|
|
Regarding your last meal before the scan: |
|
|
Ask about the use of medication prescribed by your physician - |
|
|
Avoid caffeine, sugar, tobacco for one day prior to your exam. |
|
|
Avoid rigorous exercise for one day prior to your exam. |
|
|
Avoid vigorous massage or muscle manipulations a day or two prior to your exam. |
|
|
Do you have diabetes? |
|
|
Are you pregnant or might be? |
"Because the radioactivity is very short-lived, your radiation exposure is extremely low. The substance amount is so small that it does not affect the normal processes of the body."
Source: radiologyinfo.org
IAEA Radiation Protection of Patients:
|
|
|
Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations http://jnm.snmjournals.org/cgi/content/full/46/4/608 |
"... "fluorodeoxyglucose (FDG - PET) is not a cancer-specific agent, and false positive findings in benign diseases have been reported in active inflammation or infection, causing false-positive results (1, 2)."
FALSE POSITIVE FINDINGS
"Inflammatory cells such as neutrophil and activated macrophages at the site of inflammation or infection show increased FDG accumulation (5). Active granulomatous processes, other infectious conditions and active fibrotic lesions have also been reported to show increased FDG accumulation and cause false-positive PET scans for malignancy."
1. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000;216:117-121
2. Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. RadioGraphics 2003;23:315-340
source: http://www.kjronline.org/abstract/files/v07n0157.pdfThink Twice Before Exercising When Getting that PET Scan -
By: Society of Nuclear Medicine | Published: Mar 8, 2006 at 07:01 - yubanet.com/
"Any type of physical activity - from tapping your feet while in the waiting room to jogging the neighborhood the day before - can affect the results of a PET scan and lead to false-positive results," said Medhat M. Osman, M.D., ScM, Ph.D
The study advises technologists to instruct the patients to minimize muscle activity during the uptake phase and to telephone patients ahead of their appointments to advise them to refrain from any excessive muscle activity at least 48 hours before a PET scan.
" the phenomenon of 18F-FDG uptake in brown fat was first discovered when PET/CT fusion images showed 18F-FDG concentration in the adipose tissue rather than in muscle or lymph node as previously assumed." http://jnm.snmjournals.org/cgi/content/full/45/1_suppl/72S#F4
SUMMARY by Mozartmom:
"Reasons you might see a light up include inflammation which could be caused by radiation, chemo, an injury, or an infection. Thymic rebound (benign activity in the thymus gland) can cause a light up in the chest. So can brown fat (dense tissue filled with blood vessels) if you get cold during the scan. Muscle activity can also cause a light up. Large scar tissue masses often will have some mild degree of light up. Rarer causes could be something like even sarcoidosis."
GUIDELINES
Value of PET imaging in Follicular Lymphoma: Discussion
|
|
PET Guidelines for Assessment of Response to Lymphoma Treatment CME (2007)
|
|
Studies Assessing the Utility of PET (in table format)
|
"One of the most important skills in PET reporting may be to recognize its limitations and be clear when a definitive answer cannot be given to the referring physician's question."
- Barrington, O'Doherty: EJNM 2003:30, suppl. 1: S117-S127
Notes taken from a presentation by Paul A Hamlin, MD:
|
Staging, such as to verify localized disease? |
|||||||
|
Distinguishing indolent from aggressive histology based on SUV measurements?
|
|||||||
|
Predicting response to treatment early? |
|
Evaluating residual masses following treatment |
|
|
Bone marrow evaluations? |
|
|
Follow up/monitoring? |
Source: Paul A Hamlin, MD - presentation
|
Some indolent lymphomas may show only low-grade FDG uptake, |
|
|
FDG uptake is non-specific (other pathology, inflammations, infections, HIV, etc), |
|
|
Clinical limitations of findings |
To evaluate treatment response or re-stage the disease be performed on the same scanner to be comparable
Source: Paul A Hamlin, MD - presentation
"Specifically, assessing response [with PET] may be useful in two possible situations:
(1) to evaluate tumor response at the end of a full course of treatment, or
(2) to predict tumor response early in the course of a prolonged treatment regimen [for aggressive lymphomas]. In the first instance, early detection of treatment failure may permit a physician to institute a second-line therapeutic approach.
In the second instance, accurately predicting treatment failure may allow the physician to substitute an alternative regimen, without subjecting the patient to the toxicity of the full course. " Peter E. Valk, MD
TRIAL SEARCH: ClinicalTrials.gov:
Also see PET Scan More Accurate Predictor of Outcome in [aggressive] Non-Hodgkin’s Lymphoma - cancerconsultants.com
Every patient is unique: Individualized therapies for NHL eurekalert.org
|
But not so fast!
Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in
|
"PET is very accurate in predicting short-term treatment failure. However, it cannot detect microscopic residual disease and thus its value is hampered by false negative results in patients relapsing later.
On the other hand, a biopsy is always indicated before salvage therapy in order to exclude false positive PET results related to inflammatory lesions or to second primary tumors." ~ G. H. M. Jerusalem, et al. - ASCO presentation
Also see:
|
Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. |
|
|
Predictive value and diagnostic accuracy of PET treated grade 1 and 2 follicular lymphoma. |
The meaning of the PET SUV scores is a very commonly asked question.
Based on some sources, a SUV ≥ 13 in the most intense lesion is highly indicative of aggressive histology, while
a SUV ≤ 6 is much more compatible with indolent lymphoma, unless the clinical course indicates otherwise
(Role of Positron Emission Tomography in Lymphoma )
However, there is variation in patients and in the equipment used. The Deauville Score addresses this variation by translating SUV values to a score of 1 to 5, based on how it compares to SUV values in the patient ... in the liver and mediastinal pool.
|
The ASCO Post, November 15, 2013 |
|
|
Role of Positron Emission Tomography in Lymphoma |
|
|
"FDG uptake in indolent lymphoma appears to be lower than in aggressive lymphomas [17]. Data on the correlation between proliferative activity and glycolysis in malignant tissue, as measured by FDG uptake, are controversial [18, 19]. To date, the correlation between FDG uptake and proliferative activity specifically in indolent lymphoma has not been studied in detail." |
NOTE: Differences in administration and tracers across centers may influence SUV values. That is, we don't know if the SUV values and reference ranges are comparable in different centers.
study: FDG-PET Demonstrates Different Metabolic Activities among Lymphoma Subtypes. abstracts.hematologylibrary.org
Results are summarized in Table 1. The highest mean SUV’s were obtained in aggressive non-Hodgkin’s lymphomas (NHL) followed by Hodgkin’s disease (HD) and indolent NHL.
|
study: Majority of Transformed Lymphomas Have High SUVs on PET Scanning Similar To Diffuse Large B Cell Lymphoma (DLBCL). Session Type: Poster Session, Board #580-II |
The SUVmax for a transformed aggressive lymphoma ranged from 3.2 - 30.2,
with a median of 10.8 and mean of 14.
16/28 (57%) patients had an SUVmax above 10; and 12/28 (43%), above 13.
|
Review article: on PET to determine grade - Medscape free login req. |
Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats |
PubMed: Utility of PET scans in mantle cell lymphoma |
|
PET scans: when and how? James Olen Armitage |
PET in mucosa-associated lymphoid tissue (MALT) lymphoma.
|
|
Positron emission tomography with PET does not visualize extranodal
|
|
FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases - annonc.oupjournals.org |
Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary (lung) nodules. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563015/
snips from Discussion section of the paper:
"The data of this study is collected from two PET centers, a phantom study is used to examine the SUV measurement on both scanners. The experiment indicates that SUV from different scanners under the same image protocols and same scintillation detector type (BGO for both scanners) can be quite different in value. ...we recommend that the follow up scans to evaluate treatment response or re-stage the disease be performed on the same scanner to be comparable. "
"The data above support that although, the SUVmax cutoff of 2.5 is a useful tool in the evaluation of large pulmonary nodules (> 1.0 cm), it has no or minimal value in the evaluation of small pulmonary nodules (≤ 1.0 cm). However, the combination of flexible value of SUVmax cutoff according to the size of the nodule, visual assessment, and CT characteristics of the nodules, in addition to pretest probability of malignancy, is the most appropriate approach to characterize small pulmonary nodules. To increase the sensitivity of the test of SUVmax cutoff for characterizing small nodules (≤ 1 cm), we recommend reducing the cutoff of less than 2.5"
Hodgkin lymphoma:
negative interim-PET cannot circumvent need for end-of-treatment-PET evaluation http://bit.ly/2bRVrFQ* The Value of PET/CT in Detecting Bone Marrow Involvement
in Patients With Follicular Lymphoma http://1.usa.gov/1S2dw0T full text (a bit technical)
* ASH Paper:
Negative Interim FDG-PET Scan Is Predictive of Superior Outcome in T Cell Lymphoma http://bit.ly/1iDzGpb
Prognostic Value of Interim and Posttherapy 18F-FDG PET/CT in Patients with Mature T-Cell and Natural Killer Cell Lymphomas http://bit.ly/QsitVu
Our study indicates that interim and posttherapy PET/CT results are 2 independent predicators of PFS and OS in T/NK-cell lymphomas. In addition, our data also imply that patients with positive results at interim or posttherapy PET/CT should be considered candidates for an intensive therapeutic strategy to improve their clinical outcome.* Hutchings, Medscape: Expert review
PET Imaging in Lymphoma http://bit.ly/19F57NU* PET Compared With CT After Rituximab Induction Therapy In Follicular Lymphoma: National Lymphocare Study http://bit.ly/1f9TRuv
We've heard expert comment that if you are PET negative after R-chemo following first treatment of FL that you probably don't need Rituxan maintenance - will do as well without it. We don't know if this is a consensus opinion though.
* Br J Haematol 2013:
Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. http://1.usa.gov/1jIvDIf* J Clin Oncol. 2013
False-Positive PET in allo but not auto SCT treatment for #lymphoma - http://1.usa.gov/1eqY9L3
* Dr. Sharman's CLL & Lymphoma Blog: CT and PET scans http://bit.ly/YNG7gd
* IAEA Radiation Protection of Patients: PET/CT Scanning http://bit.ly/Sog0eu
Includes information on protection of children, pregnant woman,
breast feeding mothers and accompanying persons